Wnt family ligands

Rho-Kinase-IN-1 is a Rho kinase (ROCK) inhibitor ( K i values of 30.5 and 3.9 nM for ROCK1 and ROCK2 , respectively) extracted from US20090325960A1, compound 1.008In VitroRho-Kinase-IN-1 is a ROCK inhibitor which can be useful for treating diseases

Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase ( ROCK ) inhibitor (ROCK2 IC 50 =3 nM). Rho-Kinase-IN-2 can be used in Huntington’s researchIn VitroRho-Kinase-IN-2 (0-10 mM, 1 hour)

Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase ( ROCK ) inhibitor (ROCK2 IC 50 =3 nM). Rho-Kinase-IN-2 can be used in Huntington’s researchIn VitroRho-Kinase-IN-2 (0-10 mM, 1 hour)

Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase ( ROCK ) inhibitor (ROCK2 IC 50 =3 nM). Rho-Kinase-IN-2 can be used in Huntington’s researchIn VitroRho-Kinase-IN-2 (0-10 mM, 1 hour)

Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase ( ROCK ) inhibitor (ROCK2 IC 50 =3 nM). Rho-Kinase-IN-2 can be used in Huntington’s researchIn VitroRho-Kinase-IN-2 (0-10 mM, 1 hour)

Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of

Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of

Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of

RKI-1313 is a ROCK inhibitor with IC 50 s of 34, 8 µM for ROCK 1 and ROCK 2, respectively. RKI-1313 shows little effect on the phosphorylation levels of ROCK substrates, migration, invasion or anchorage-independent growthForm:SolidIC50&amp

RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC 50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2

RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC 50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2

RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC 50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2